Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant vs Adjuvant Toripalimab and Gemcitabine in Recurrent NPC
NCT06235203Phase 3Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab, gemcitabine in nasopharyngeal carcinoma (NPC), sponsored by Eye and ENT Hospital of Fudan University. Started Jul 2024; status: recruiting.
02
Drugs
toripalimabgemcitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06235203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235203.